Proteomics International Laboratories Ltd. (AU:PIQ) has released an update.
Proteomics International Laboratories Ltd has partnered with Growth Medics B.V. to boost the European commercialization of its PromarkerD test, a predictive diagnostic for diabetic kidney disease. The collaboration aims to leverage Growth Medics’ sales expertise and extensive network to establish new partnerships and expand market reach, targeting key countries including the Netherlands, Belgium, Italy, and Spain. This strategic move is expected to enhance patient care and address the ‘silent pandemic’ of diabetes, which has a significant impact on healthcare systems in Europe.
For further insights into AU:PIQ stock, check out TipRanks’ Stock Analysis page.
